DRTS
Alpha Tau Medical Ltd.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
7.69
P/S
0.00
EV/EBITDA
-14.61
DCF Value
$-0.02
FCF Yield
-5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.3%
ROA
-40.0%
ROIC
17.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-12.1M | $-0.14 |
| FY 2025 | $0.00 | $-42.6M | $-0.53 |
| Q3 2025 | $0.00 | $-11.7M | $-0.14 |
| Q2 2025 | $0.00 | $-10.1M | $-0.13 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
1.05
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.